Try our Advanced Search for more refined results

Juno Therapeutics, Inc. v. Kite Pharma, Inc.

  1. January 14, 2022

    Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win

    The full Federal Circuit said Friday that it will not review a panel decision wiping out Bristol-Myers Squibb subsidiary Juno Therapeutics' $1.2 billion patent infringement victory against Gilead's Kite Pharma Inc.

  2. December 13, 2021

    The Biggest Patent Rulings Of 2021

    The U.S. Supreme Court preserved America Invents Act reviews by creating a new review process, and narrowed application of a rule that could allow more inventors to challenge their own patents. Here's a look back at the biggest patent cases of the year.

  3. November 12, 2021

    Amgen Backs Juno's Fed. Circ. Bid To Revive $1.1B Judgment

    Biotech giant Amgen has joined forces with cancer research centers to back Bristol-Myers Squibb subsidiary Juno Therapeutics' efforts to restore a $1.1 billion patent judgment against Gilead's Kite Pharma that was wiped out by the Federal Circuit, arguing that the ruling has added to the uncertainty over securing pharmaceutical and biotech patents.

  4. October 28, 2021

    Juno Urges Fed. Circ. To Undo 'Mischief' In Wiping $1B IP Win

    Bristol-Myers Squibb subsidiary Juno Therapeutics is asking the full Federal Circuit to reconsider its reversal of a $1.1 billion judgment against Gilead's Kite Pharma Inc., slamming the "mischief" caused by the panel deeming its patent invalid for lack of adequate written description support.

  5. September 02, 2021

    The Latest Fed. Circ. Antibody Rulings You Need To Know

    Since the beginning of 2021, the Federal Circuit has invalidated several antibody patents in cases that have deeply split the pharmaceutical industry and taken down a billion-dollar verdict. Here is a look at how the judges are handling these infringement and invalidity fights.

  6. August 26, 2021

    Fed. Circ. Wipes Out $1.1B Juno IP Win On Cancer Drug

    The Federal Circuit on Thursday reversed a $1.1 billion judgment against Gilead's Kite Pharma Inc. for infringing Bristol-Myers cancer immunotherapy patent, ruling that the patent is invalid because it lacks adequate written description support.

  7. July 06, 2021

    Fed. Circ. Judge Unsure IP At Heart Of $1.1B Juno Win Is Valid

    The Federal Circuit's chief judge appeared receptive Tuesday to Kite Pharma's argument that a Juno Therapeutics drug patent is too broad to be valid, potentially calling into question Juno's more than $1.1 billion infringement win during the appellate court's first in-person hearing since the arrival of the COVID-19 pandemic.

  8. July 01, 2021

    Fed. Circ. Forecast: Kite Takes Aim At Juno's $1.2B IP Win

    The Federal Circuit next week will hear Kite Pharma's appeal of a $1.2 billion verdict in favor of Juno Therapeutics in a case over a cancer treatment patent, marking the first time the appeals court will hear a case in-person since the start of the pandemic. Here's a look at that case — plus all the other major patent cases facing the court in the coming week.

  9. June 22, 2021

    Fed. Circ. Will Return To In-Person Arguments In August

    After almost 15 months of holding arguments remotely, the Federal Circuit plans to open its doors to lawyers again in late August, but will test out new in-person COVID-19 protocols in two cases next month, including Kite Pharma Inc.'s high-profile appeal of a $1.2 billion patent infringement judgment against it.

  10. December 15, 2020

    Juno Tells Fed. Circ. To Uphold Its $1.2B Patent Win Over Kite

    Because Kite Pharma Inc. "brazenly chose" to infringe a cancer treatment patent with its Yescarta treatment, the Federal Circuit should not undo a lower court's $1.2 billion decision against it, Juno Therapeutics Inc. said Monday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!